Lack of association between KRAS mutations and 18F-FDG PET/CT in Caucasian metastatic colorectal cancer patients.
| Τίτλος | Lack of association between KRAS mutations and 18F-FDG PET/CT in Caucasian metastatic colorectal cancer patients. |
| Publication Type | Journal Article |
| Year of Publication | 2014 |
| Authors | Krikelis, D., Skoura E., Kotoula V., Rondogianni P., Pianou N., Samartzis A., Xanthakis I., Fountzilas G., & Datseris I. E. |
| Journal | Anticancer Res |
| Volume | 34 |
| Issue | 5 |
| Pagination | 2571-9 |
| Date Published | 2014 May |
| ISSN | 1791-7530 |
| Λέξεις κλειδιά | Adult, Aged, Colorectal Neoplasms, DNA Mutational Analysis, Female, Fluorodeoxyglucose F18, Humans, Male, Middle Aged, Multimodal Imaging, Mutation, Positron-Emission Tomography, Proto-Oncogene Proteins, Radiopharmaceuticals, ras Proteins, Real-Time Polymerase Chain Reaction, Retrospective Studies, Tomography, X-Ray Computed |
| Abstract | BACKGROUND: Although Kirsten rat sarcoma (KRAS) gene mutational testing is essential for the optimal design of therapeutic strategies for colorectal cancer, it is not always feasible or reliable. In this retrospective study, we examined whether (18)F-Fluorodeoxyglucose positron-emission tomography/computed tomography ((18)F-FDG PET/CT) scans can serve as a surrogate examination for KRAS mutational testing.PATIENTS AND METHODS: KRAS codon 12 and 13 mutational status was tested in 44 colorectal primary tumors and was compared with the (18)F-FDG PET/CT maximum standardized uptake value (SUVmax) values of the respective metastatic lesions. Glucose transporter-1 (GLUT1) mRNA levels were also measured in colorectal primary tumors.RESULTS: No statistically significant correlation between (18)F-FDG PET/CT SUVmax values and KRAS mutation status was found (parametric t-test: p=0.4753; non-parametric Kruskal-Wallis test: p=0.51). This result cannot be attributed to the effect of differing GLUT1 mRNA levels, as shown by multivariate analysis.CONCLUSION: Our study failed to promote (18)F-FDG PET/CT uptake as a surrogate examination for KRAS mutation testing. |
| Alternate Journal | Anticancer Res. |
| PubMed ID | 24778079 |
